Equillium, Inc. (0FY.F)
| Previous close | 1.5220 |
| Open | 1.5860 |
| Bid | 1.4360 x 0 |
| Ask | 1.4880 x 0 |
| Day's range | 1.5860 - 1.7000 |
| 52-week range | 0.4035 - 2.7050 |
| Volume | |
| Avg. volume | 408 |
| Market cap | 59.933M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Equillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical Highlights
LA JOLLA, Calif., May 09, 2024--Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced financial results for the first quarter 2024 and highlights in clinical development.
- Business Wire
Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists
LA JOLLA, Calif., May 07, 2024--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that a poster was presented at IMMUNOLOGY2024, the annual meeting of The American Association of Immunologists. The meetings are taking place at McCormick Place Convention Center in Chicago, Illinois, May 3 – 7.
- Business Wire
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
LA JOLLA, Calif., April 03, 2024--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that on April 1, 2024, the Compensation Committee of Equillium’s Board of Directors granted an inducement award consisting of a nonstatutory stock option to purchase 10,000 shares of common stock to a new employee under Equillium’s 2024 Inducement Plan. The Compensation Committee appr
